GLP-1 side effects, ranked by frequency
Nausea is the headline. The full picture from registration trials includes diarrhea, fatigue, gallstones and a few rare-but-serious events worth knowing about before you start.
- Nausea leads at ~44 percent on Wegovy (STEP-1; 33 percent on Zepbound 15 mg in SURMOUNT-1). Diarrhea, constipation and vomiting follow.
- The titration weeks are the hard part. GI effects cluster in weeks 1 to 16 and fade as each dose settles. Most discontinuations happen in the first month.
- Serious events are rare. Pancreatitis runs about 0.2 percent annualized, gallbladder events 1 to 2 percent over 68 weeks, severe gastroparesis about 1 percent.
- The suicidality review came back clean. MHRA and EMA reviewed the 2023 to 2024 reports and found no causal link.
- Slow titration is your main lever. Programs that allow dose holds have fewer side-effect dropouts; ask about them before signing up.
| Fact | Value | Source | Verified |
|---|---|---|---|
| Nausea on Wegovy 2.4 mg | 44% (STEP-1) | STEP-1, NEJM 2021 | May 2026 |
| Nausea on Zepbound 15 mg | 33% (SURMOUNT-1) | SURMOUNT-1, NEJM 2022 | May 2026 |
| Diarrhea on Wegovy | 32% | STEP-1 | May 2026 |
| Pancreatitis annualized rate | ~0.2% on GLP-1 therapy | FAERS, pooled trial data | May 2026 |
| Gallbladder events | 1 to 2% over 68 weeks | STEP-1, SURMOUNT-1 | May 2026 |
| MHRA/EMA suicidality review | No causal link (2023 to 2024) | MHRA Drug Safety Update; EMA PRAC | May 2026 |
About one in three patients quits a GLP-1 within the first six months. The most common reason is not cost or weight-loss disappointment. It is GI side effects.
This post ranks the side effects you'll actually encounter, from most-common to most-serious, with the realistic % chance of each.
Most common (>20% of patients)
| Side effect | Wegovy | Zepbound | What helps |
|---|---|---|---|
| Nausea | ~44% | ~29% | Smaller meals, skip greasy food, inject early in the week so the worst hits days you can rest through |
| Diarrhea | ~31% | ~23% | Hydrate more than feels necessary; appetite suppression hides fluid loss |
| Constipation | ~23% | ~17% | Fiber and water first, stool softeners for stubborn cases |
| Vomiting | ~25% | ~12% | More than once or twice a week means the dose is too high or escalating too fast |
Nausea defines the class: worst during dose titration, usually subsiding one to two weeks after each increase, mostly mild to moderate. The medication slows motility everywhere. About 5 percent of patients oscillate between diarrhea and constipation.
Common (5-20%)
Fatigue / low energy (~11% on Wegovy): Often dietary, patients eat ~30-40% fewer calories on a GLP-1 and don't always replace the lost macronutrients. A protein-forward diet (1g per kg of bodyweight per day) addresses most cases.
Headache (~14% on Wegovy): Mild and usually self-resolving. Can be dehydration-driven; check water intake first.
Heartburn / acid reflux (~5-10%): Slowed gastric emptying means food sits longer; reflux can worsen. Avoid eating 3 hours before lying down; PPIs help if persistent.
Injection site reactions (~5%): Redness, itching or small lumps at the injection site. Rotate injection sites; usually resolves within a few days.
Less common but worth knowing (1-5%)
Gallstones / cholecystitis (~1.6% Wegovy vs 0.7% placebo): Rapid weight loss is associated with gallstone formation regardless of mechanism. GLP-1s appear to slightly increase risk above the baseline weight-loss-driven rate. Cholecystectomy is the standard fix when symptomatic. If you have a known gallbladder issue, flag it to your prescriber before starting.
Gastroparesis (delayed gastric emptying, severe form): ~1% of patients develop more pronounced gastric emptying delay than expected. Symptoms include feeling full hours after eating, persistent vomiting of undigested food, abdominal pain. Usually reversible after stopping the medication, but can persist in rare cases. This was the basis of high-profile lawsuits in 2023-2024.
Pancreatitis (~0.2-0.4%): Rare but serious. Symptoms: severe upper abdominal pain radiating to back, vomiting, fever. Stop the medication immediately and seek care. Risk increases in patients with prior pancreatitis history; most prescribers screen for this at intake.
Hair loss / thinning (~3-5%, anecdotal): Not in registration trial side-effect tables but well-documented in patient communities. Usually telogen effluvium driven by rapid weight loss and reduced caloric intake rather than the medication itself. Reverses 3-6 months after weight stabilizes; biotin and adequate protein intake help.
Rare but serious (<1%)
Medullary thyroid carcinoma (MTC): Black-box warning on all GLP-1 receptor agonists based on rodent studies. No human signal has emerged in 15+ years of post-market use. Patients with personal or family history of MTC or MEN2 syndrome should not take GLP-1s.
Severe hypoglycemia (very rare in non-diabetics): GLP-1s have a low intrinsic hypoglycemia risk because they're glucose-dependent. Risk increases for patients on sulfonylureas or insulin. Non-diabetic weight-loss patients essentially never experience clinically significant hypoglycemia.
Diabetic retinopathy worsening: Specifically observed in long-term diabetic patients on semaglutide; rapid HbA1c reduction can transiently worsen retinopathy. Not relevant for most weight-loss-only patients.
Severe allergic reactions / anaphylaxis: Reported in <0.1%. Stop and seek emergency care if you develop hives, swelling or breathing difficulty after injection.
What this means for program choice
Most side effects are dose-titration phenomena. Programs that titrate slower (Noom Med's microdose protocol, Form Health's clinician-driven titration) tend to have lower discontinuation rates. Programs that escalate fast (some async-only programs) may produce more side-effect-driven dropouts.
If you're starting GLP-1 and worried about side effects, ask whether your program offers dose holds (staying at a tolerable dose for an extra month before escalating) without insurance complications. Form Health, 9amHealth, and Knownwell all explicitly support clinician-led titration adjustments. Async-only flat-rate programs can usually accommodate dose holds but you may need to ask explicitly.
Frequently asked questions
What is the most common GLP-1 side effect?
Nausea. In STEP-1, 44 percent of Wegovy 2.4 mg patients reported nausea at some point. In SURMOUNT-1, 33 percent of Zepbound 15 mg patients did. Most cases are mild to moderate and concentrated in the titration phase. Slowing the dose escalation, eating smaller portions, and avoiding fatty meals reduce the rate.
Is pancreatitis a real risk on GLP-1?
A small signal exists. The annualized rate of acute pancreatitis on GLP-1 therapy runs around 0.2 percent based on FAERS and pooled trial data. That is roughly 2 to 3 times the background rate for similar patient populations. Personal history of pancreatitis is a contraindication. Stop the medication and seek care for severe persistent abdominal pain radiating to the back.
Do GLP-1 medications cause gallstones?
Yes, at a low rate. Roughly 1 to 2 percent of patients in 68-week trials had gallbladder events. The mechanism is thought to relate to rapid weight loss rather than the drug itself. Right upper quadrant pain after fatty meals, jaundice, or fever warrants evaluation. Most gallbladder events resolve with cholecystectomy and do not require permanent GLP-1 discontinuation.
Is the suicidal-ideation signal on GLP-1 real?
MHRA and EMA both reviewed the 2023 to 2024 case reports. Both concluded no causal link between GLP-1 therapy and suicidal ideation. The signal appears to reflect the background rate of mental health events in the population starting weight-loss treatment rather than a drug effect. Patients on SSRIs or with active depression should still be screened before starting.
When do side effects usually go away?
Most GI side effects (nausea, vomiting, diarrhea) decrease meaningfully after the titration phase, typically by week 12 to 16. Constipation can persist longer. Patients who tolerate the maintenance dose for one full month usually tolerate it long-term. About 10 to 15 percent of patients discontinue inside the first month because of side effects.
Compare these programs
